Wakefield Asset Management LLLP Takes Position in Omnicell, Inc. (NASDAQ:OMCL)

Wakefield Asset Management LLLP acquired a new stake in shares of Omnicell, Inc. (NASDAQ:OMCL) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 23,611 shares of the company’s stock, valued at approximately $1,051,000. Wakefield Asset Management LLLP owned about 0.05% of Omnicell as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in OMCL. Van ECK Associates Corp grew its holdings in Omnicell by 47.0% during the 4th quarter. Van ECK Associates Corp now owns 985 shares of the company’s stock valued at $44,000 after buying an additional 315 shares during the last quarter. First Horizon Advisors Inc. grew its position in shares of Omnicell by 36.3% during the fourth quarter. First Horizon Advisors Inc. now owns 1,333 shares of the company’s stock worth $59,000 after buying an additional 355 shares in the last quarter. KBC Group NV lifted its holdings in Omnicell by 60.8% during the 4th quarter. KBC Group NV now owns 2,057 shares of the company’s stock worth $92,000 after buying an additional 778 shares during the last quarter. 1620 Investment Advisors Inc. grew its position in shares of Omnicell by 230.1% during the 3rd quarter. 1620 Investment Advisors Inc. now owns 2,212 shares of the company’s stock valued at $96,000 after buying an additional 1,542 shares during the last quarter. Finally, CIBC Asset Management Inc acquired a new stake in Omnicell in the fourth quarter worth $201,000. Institutional investors and hedge funds own 97.70% of the company’s stock.

Omnicell Stock Down 3.2 %

Shares of NASDAQ OMCL opened at $38.47 on Friday. The stock has a market cap of $1.78 billion, a P/E ratio of 142.49, a P/E/G ratio of 7.53 and a beta of 0.78. Omnicell, Inc. has a 52-week low of $25.12 and a 52-week high of $55.74. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.22 and a current ratio of 1.37. The firm has a 50 day moving average price of $42.53 and a 200 day moving average price of $43.82.

Omnicell (NASDAQ:OMCL) last issued its quarterly earnings results on Thursday, February 6th. The company reported $0.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.57 by ($0.12). Omnicell had a net margin of 1.13% and a return on equity of 3.82%. Analysts expect that Omnicell, Inc. will post 1.09 EPS for the current year.

Insider Buying and Selling

In other news, Director Mark W. Parrish sold 12,000 shares of the business’s stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $47.30, for a total transaction of $567,600.00. Following the completion of the transaction, the director now owns 58,427 shares of the company’s stock, valued at approximately $2,763,597.10. The trade was a 17.04 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 2.64% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on OMCL shares. Bank of America dropped their target price on Omnicell from $54.00 to $46.00 and set a “neutral” rating on the stock in a report on Monday, January 6th. Wells Fargo & Company cut their target price on shares of Omnicell from $49.00 to $40.00 and set an “equal weight” rating for the company in a research report on Monday, January 13th. JPMorgan Chase & Co. increased their price objective on Omnicell from $37.00 to $44.00 and gave the stock a “neutral” rating in a report on Thursday, November 21st. Craig Hallum raised their target price on Omnicell from $45.00 to $64.00 and gave the company a “buy” rating in a report on Thursday, October 31st. Finally, Barclays raised their target price on shares of Omnicell from $39.00 to $58.00 and gave the company an “equal weight” rating in a research note on Thursday, October 31st. Five equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, Omnicell presently has a consensus rating of “Hold” and a consensus price target of $52.33.

Omnicell Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.